Theravance Biopharma
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $16,868 | $14,256 | $14,503 | $17,565 |
Gross Profit | 16,868 | 4,302 | 12,970 | 13,232 |
EBITDA | -8,660 | -13,598 | -8,240 | -2,675 |
EBIT | -9,422 | -14,577 | -9,773 | -4,394 |
Net Income | -12,698 | -16,529 | -11,664 | -8,511 |
Net Change In Cash | 16,868 | 14,256 | 14,503 | 17,565 |
Free Cash Flow | -5,211 | -4,451 | -1,113 | -1,531 |
Cash | 23,378 | 46,345 | 53,835 | 39,545 |
Basic Shares | 49,038 | 48,747 | 48,283 | 49,415 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $57,424 | $51,346 | $55,311 | $71,857 |
Gross Profit | 16,803 | 44,757 | 48,025 | -189,095 |
EBITDA | -40,867 | -79,857 | -249,389 | -293,999 |
EBIT | -46,919 | -86,446 | -256,675 | -300,643 |
Net Income | -55,193 | -92,824 | -199,426 | -278,017 |
Net Change In Cash | 57,424 | 51,346 | 55,311 | 71,857 |
Cost of Revenue | 208,212 | 8,496 | 23,403 | |
Free Cash Flow | -29,485 | -187,563 | -211,264 | -257,019 |
Cash | 39,545 | 298,172 | 89,959 | 81,467 |
Basic Shares | 55,303 | 73,591 | 69,461 | 62,345 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.05 |
2024-06-30 | -$0.28 |
2024-03-31 | -$0.24 |
2023-12-31 | -$0.17 |
